Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
作者信息
Olujohungbe A, Cinkotai K I, Yardumian A
出版信息
BMJ. 1998 Jun 6;316(7146):1689. doi: 10.1136/bmj.316.7146.1689.
Abstract
摘要
相似文献
1
Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
BMJ. 1998 Jun 6;316(7146):1689. doi: 10.1136/bmj.316.7146.1689.
2
Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
Lancet Glob Health. 2015 Mar;3(3):e124-5. doi: 10.1016/S2214-109X(14)70371-7.
3
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093.
4
Hydroxyurea for sickle cell anemia.
N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9.
5
Hydroxurea and sickle cell disease: Its been a long, long time coming.
Pediatr Blood Cancer. 2010 Feb;54(2):185-6. doi: 10.1002/pbc.22340.
6
Hydroxyurea for the treatment of sickle cell anemia.
N Engl J Med. 2008 Mar 27;358(13):1362-9. doi: 10.1056/NEJMct0708272.
7
Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Blood Adv. 2018 Nov 30;2(Suppl 1):30-32. doi: 10.1182/bloodadvances.2018GS110347.
8
Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease.
Blood. 2021 Feb 11;137(6):856-859. doi: 10.1182/blood.2020008146.
9
[Edifying affair of hydroxycarbamid].
Rev Med Suisse. 2008 Apr 9;4(152):940.
10
Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
Ann Intern Med. 2011 Nov 15;155(10):722-4. doi: 10.7326/0003-4819-155-10-201111150-00024.
引用本文的文献
1
Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.
Ann Hematol. 2020 May;99(5):937-945. doi: 10.1007/s00277-020-03987-7. Epub 2020 Mar 12.
2
Experiences of hospital care and treatment-seeking behavior for pain from sickle cell disease: qualitative study.
West J Med. 1999 Nov;171(5-6):306-13.
3
Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.
BMJ. 1999 Jun 12;318(7198):1585-90. doi: 10.1136/bmj.318.7198.1585.
4
Register cannot replace prospective studies in sickle cell disease.
BMJ. 1999 Mar 6;318(7184):671. doi: 10.1136/bmj.318.7184.671a.
5
European register of patients with sickle cell disease treated with hydroxyurea is being set up.
BMJ. 1998 Aug 22;317(7157):541-2. doi: 10.1136/bmj.317.7157.541a.
本文引用的文献
1
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.
Blood. 1996 Sep 15;88(6):1960-4.
2
Novel treatment options in the severe beta-globin disorders.
Br J Haematol. 1995 Oct;91(2):263-8. doi: 10.1111/j.1365-2141.1995.tb05288.x.
3
Mortality in sickle cell disease. Life expectancy and risk factors for early death.
N Engl J Med. 1994 Jun 9;330(23):1639-44. doi: 10.1056/NEJM199406093302303.
4
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001.
5
Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.
Nouv Rev Fr Hematol (1978). 1994 Oct;36(5):367-72.
6
Sickle cell disease in North London.
Br J Haematol. 1987 Aug;66(4):543-7. doi: 10.1111/j.1365-2141.1987.tb01342.x.
7
Pain in sickle cell disease. Rates and risk factors.
N Engl J Med. 1991 Jul 4;325(1):11-6. doi: 10.1056/NEJM199107043250103.
8
Comparison of homozygous sickle cell disease in northern Greece and Jamaica.
Lancet. 1990 Mar 17;335(8690):637-40. doi: 10.1016/0140-6736(90)90419-6.
Zotero 插件